Drug Patent Watch

DECEMBER 9, 2024

Scientists in this field analyze the chemical compounds in plants, animals, and microorganisms to discover potential new drugs. “Pharmacognosy is the bridge between traditional medicine and modern pharmaceutical science, offering a treasure trove of potential new drugs waiting to be discovered.”

Compounding 89

Compounding Drug Development Documentation Pharmaceutical Companies 89

Express Pharma

JUNE 11, 2025

For example, this painstaking work ensures that entities like proteins are uni- formly named and categorised across all sources and datasets for drug development purposes to enable target identification.

Data Entry 65

Data Entry Compounding Documentation Drug Development 65

European Pharmaceutical Review

JULY 24, 2023

A paper published in Pharmaceutics has proposed how a personalised preparation quality assurance programme can achieve this when these products are developed in compounding laboratories. PACMI selects a drug on a quarterly basis. It requests that compounding laboratories adhering to the programme send samples of it.

Compounding 93

Compounding Documentation Drug Development 93

Pharmaceutical Technology

JUNE 15, 2023

Drug development is already a difficult endeavor, with the vast majority of R&D efforts failing to produce a market-worthy product. Even reaching the clinical trial phase offers no guarantees, as only 12% of such drugs receive U.S. While this process is essential, it’s also slow, expensive and unpredictable.

Drug Development 52

Drug Development Adverse Reactions Compounding Dosage 52

Syner-G

SEPTEMBER 15, 2023

This shift from a linear to a network approach enhances the potential for one drug to target multiple sites. Structure-based drug design has evolved, facilitating the exploration of novel chemical probes and lead compound potency, and molecular docking utilizes target structures to predict interactions and offers simplicity and speed.

Drug Development 59

Drug Development Documentation Process Improvement Compounding 59

European Pharmaceutical Review

JULY 13, 2023

3 With established drug development pathways, we are accustomed to a rigid structure of translation from bench to bedside. While this is essential in the interrogation of novel compounds for which we know very little about their efficacy and safety, it is also true that some biomedical research is highly wasteful.

Compounding 98

Compounding Drug Development Clinical Pharmacology Documentation 98

European Pharmaceutical Review

JULY 4, 2024

The FDA’s role in the regulation of botanical drug products includes an assessment of their safety and efficiency 5 but insufficient evidence for efficacy is one of the most common reasons why new drug candidates fail to reach this step. The worldwide trend of using botanical drugs and strategies for developing global drugs.

Drug Development 103

Drug Development Documentation Biosimilars Compounding 103